James Cregg

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato et al. · Cancer Discovery · 2024 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

James Cregg, Anne Edwards, Stephanie Chang et al. · Journal of Medicinal Chemistry · 2025 · 72 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

G. Leslie Burnett, Yu Chi Yang, James B. Aggen et al. · Journal of Medicinal Chemistry · 2022 · 63 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers

James Cregg, Kristof Pota, Aidan C.A. Tomlinson et al. · Journal of Medicinal Chemistry · 2025 · 40 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Abstract PR10: Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions <i>in vivo</i>

Christopher J. Schulze, Alun Bermingham, Tiffany J. Choy et al. · Molecular Cancer Therapeutics · 2019 · 16 citations

Medicine, Oncology, Pharmacology +16